Edition:
United Kingdom

Strides Shasun Ltd (STSA.NS)

STSA.NS on National Stock Exchange of India

403.20INR
11:25am BST
Change (% chg)

Rs11.15 (+2.84%)
Prev Close
Rs392.05
Open
Rs396.00
Day's High
Rs440.50
Day's Low
Rs396.00
Volume
24,064,339
Avg. Vol
1,030,774
52-wk High
Rs1,102.20
52-wk Low
Rs333.30

Select another date:

Wed, May 2 2018

BRIEF-India's Strides Shasun Gets U.S. FDA Nod For Cinacalcet Hydrochloride Tablets

* STRIDES SHASUN RECEIVES USFDA APPROVAL FOR CINACALCET HYDROCHLORIDE TABLETS

BRIEF-Strides Shasun To Divest Holding In Remaining API Asset At Ambernath

* SAYS TO DIVEST ITS HOLDING IN REMAINING API ASSET AT AMBERNATH TO SOLARA ACTIVE PHARMA SCIENCES LIMITED

BRIEF-Strides Shasun Says NCLT Approves Co's Scheme Of Arrangement With Sequent Scientific And Solara Active Pharma Sciences

* SAYS NCLT APPROVED COMPOSITE SCHEME OF ARRANGEMENT BETWEEN CO, SEQUENT SCIENTIFIC AND SOLARA ACTIVE PHARMA SCIENCES Source text - http://bit.ly/2HLmsbG Further company coverage:

BRIEF-India's Strides Shasun Gets U.S. FDA Nod For Cyproheptadine Hydrochloride Tablets

* GETS USFDA APPROVAL FOR CYPROHEPTADINE HYDROCHLORIDE TABLETS

BRIEF-Strides Shasun Gets U.S. FDA Approval For Ibuprofen Softgel OTC Capsules

* SAYS CO GETS U.S. FDA APPROVAL FOR IBUPROFEN SOFTGEL OTC CAPSULES Source text - https://bit.ly/2Gu3qoC Further company coverage:

BRIEF-Sequent Scientific Says NCLT ‍Approved Composite Scheme Between Co, Strides Shasun, Solara Active Pharma Sciences

* NCLT ‍APPROVED COMPOSITE SCHEME INVOLVING DEMERGER OF COMMODITY API BUSINESS OF STRIDES, HUMAN API BUSINESS OF CO INTO SOLARA Source text - http://bit.ly/2pyeydJ Further company coverage:

BRIEF-Strides Shasun Gets U.S. FDA Approval For Efavirenz Tablet

* PRODUCT TO BE MANUFACTURED AT ORAL DOSAGE FACILITY AT BANGALORE; MARKETED BY STRIDES PHARMA INC IN U.S. MARKET Source text - http://bit.ly/2tKMrfZ Further company coverage:

BRIEF-Strides Shasun Appoints Arun Kumar As Exec Chairman‍​

* SAYS APPOINTED ARUN KUMAR AS EXECUTIVE CHAIRMAN‍​ Source text: http://bit.ly/2Hqk1Kg Further company coverage:

BRIEF-Strides Shasun To Launch Ranitidine Tablets In U.S.

* PRODUCT, TO BE LAUNCHED FOR U.S. MARKETS, WILL BE BACKWARD INTEGRATED AND MANUFACTURED AT JV’S ORAL DOSAGE FACILITY IN CHENNAI Source text: http://bit.ly/2tp4Yyk Further company coverage:

BRIEF-Strides Shasun To Launch Ranitidine OTC Tablets In U.S.

* PRODUCT WILL BE MANUFACTURED AT THE JV'S (COMPANY'S 50:50 JV WITH VIVIMED LABS) ORAL DOSAGE FACILITY IN CHENNAI‍​ Source text: http://bit.ly/2oqiNHS Further company coverage:

Select another date: